Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how efgartigimod affects thyroid function in adults with Graves Disease GD, focusing on its safety, tolerability, and impact on antibody levels and immune response. This Phase 3 study compares efgartigimod with placebo in adults whose GD is not adequately controlled with antithyroid drugs, aiming to better understand its effects on thyroid hormone levels and disease control. Participants will be randomly assigned to receive either efgartigimod PH20 subcutaneous injections via prefilled syringe or placebo during the initial double-blinded treatment period part A and treatmentobservation period part B. Those who respond may continue to an open-label treatmentobservation phase part C receiving efgartigimod. Treatment and observation durations vary, with total participation lasting from approximately 63 to 135 weeks depending on individual response. During the study, participants will undergo regular assessments of thyroid hormone levels fT3, fT4, TSH, antibody levels, and immune responses to evaluate treatment effects. Safety and tolerability will be closely monitored, and researchers will track changes in thyroid-related symptoms and quality of life. The main outcome is the percentage of participants achieving normal thyroid hormone levels without antithyroid drugs by week 24. Participants will be followed for up to nearly three years to observe long-term effects and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.